Panlabs Biologics Inc. officially completed a technology transfer agreement in 2025 with the Agricultural Technology Research Institute (ATRI), acquiring the key Pichia pastoris expression system. This platform is now integrated into Panlabs’ comprehensive microbial development platform, marking a new milestone in Taiwan’s biopharmaceutical sector for high-efficiency recombinant protein expression.

The Pichia pastoris system introduced by Panlabs features flexible protein expression capabilities and robust yields, making it ideally suited for the development and production of a wide range of high-value recombinant proteins.

With over 50 years of experience in microbial strain development, fermentation process optimization, and production platforms for high-value natural products, Panlabs has built a portfolio of diverse technological platforms and product pipelines, including:

• Microbial CRO/CDMO Service Platform: Providing services from strain engineering and process optimization to commercial-scale production.
• Global Microbial Strain Bank: A comprehensive collection and commercialization mechanism supporting customized strain development and large-scale production.
• ADC Drug Development Platform: Supporting linker-payload screening and early-stage development of ADC payloads such as Ansamitocin, Mertansine, Calicheamicin, Belotecan, and Nemorubicin.
• Recombinant Protein Development Platform: Enabling production of various recombinant proteins, including cytokines, growth factors, structural proteins, and industrial enzymes.
• Exosome Development Platform: Focused on exosomes derived from Lactobacillus, targeting applications in skin regeneration and cosmeceuticals.
• PDRN (Polydeoxyribonucleotide): Developing biologically active polynucleotide-based products for aesthetic and therapeutic applications.

Panlabs Biologics and ATRI Signing Ceremony: